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Abstract
Background: Atrial fibrillation is a common serious cardiac arrhythmia. Knowing the prevalence
of atrial fibrillation and documentation of medical management are important in the provision of
primary care. This study sought to determine the prevalence of atrial fibrillation in a primary care
population and to identify and quantify the treatments being used for stroke prevention in this
group of patients.
Methods: A prevalence study through chart audit was conducted in the family medicine practice
at the Sunnybrook campus of the Sunnybrook and Women's College Health Sciences Centre. The
main outcome measures were the prevalence of atrial fibrillation in our primary care practice and
the use of warfarin for stroke prevention in this population.
Results: 261 patients in our practice have atrial fibrillation. The overall prevalence in our family
practice unit is 3.9%. When considering patients aged 60 and over, the prevalence rises to 12.2%.
204 of our patients with atrial fibrillation (78.2%) are currently being treated with warfarin. Another
21 patients were previously treated and discontinued for a number of reasons. Of the 57 patients
not currently treated with warfarin, 44 are treated with ASA, 2 with ticlopidine, and 11 are
receiving no preventative treatment.
Conclusions: The prevalence of atrial fibrillation in our practice is higher than the range of
prevalence reported in the general literature. However, our coverage with warfarin treatment
exceeds previous reports in the literature.
Background
Atrial fibrillation is an arrhythmia associated with serious
morbidity, mortality and significant health services utili-
zation. Atrial fibrillation is associated with 15% of cere-
bral vascular accidents [1,2]. It has been conclusively
shown that patients with non-valvular atrial fibrillation
have five times the risk of stroke over the general popula-
tion with an absolute risk of 2–6% per year in those with-
out a previous CVA and 12–13% in those who have had a
previous cerebrovascular event [3]. Despite its impor-
tance, atrial fibrillation frequently remains unrecognized
in general practice.
Warfarin is an effective medical therapy for the prevention
of stroke [4]. Prescribing of warfarin has increased as
much as 4-fold over the last decade, likely as a result of the
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dissemination of clinical trials [5,6], but evidence suggests
that physicians are still treating anywhere from 10–50%
of those patients with atrial fibrillation who would benefit
from warfarin [7–11]. Furthermore, those who would
benefit the most from treatment are elderly patients who
are usually the group least likely to be treated [12]. The
majority of medical care for this population is delivered in
a primary care setting. Therefore, it is important to deter-
mine the number of patients in a practice with atrial fibril-
lation and to evaluate whether or not they are receiving
optimum therapy.
The purpose of this study was twofold: to determine the
prevalence of atrial fibrillation in an academic family
practice setting and to document the treatments pre-
scribed for this condition.
Methods
In this study, a complete detailed chart audit was per-
formed to identify all patients with atrial fibrillation and
the current treatment they are receiving. The audit com-
prised all patients registered in the practice who were seen
at least once in the family practice unit during a 2 year pe-
riod from January 1, 1999 to December 31, 2000 inclu-
sive. The family practice unit consists of twelve full time
equivalent physicians and six full-time equivalent nurses
divided into three teams. These teams provide anticoagu-
lation monitoring including venipuncture and warfarin
dose adjustment. INR results are kept in a dedicated bind-
er in the nursing stations for each team. There is an anti-
coagulation clinic also on site, but family practice
provides anticoagulation to over 75% of patients receiv-
ing warfarin. The study was approved by the Research Eth-
ics Board of the Sunnybrook and Women's College Health
Sciences Centre.
Inclusion/Exclusion Criteria
Data was gathered on all patients identified as having
chronic atrial fibrillation or at least one episode of parox-
ysmal atrial fibrillation during the two year period from
January 1, 1999 to December 31, 2000. The presence of
atrial fibrillation was based on documentation in the con-
tinuous patient profile, the clinic notes, consultant letters,
emergency room or hospital discharge summaries, elec-
trocardiograms, Holter monitors, echocardiograms, or
stress test reports. Variables collected included age, sex,
anti-coagulation treatment, and complications.
Analysis
Data was abstracted by a trained chart abstracter and veri-
fied by one of the study investigators (LC). All data was
entered into a Microsoft database. Prevalence was calcu-
lated using the number of persons identified with atrial fi-
brillation divided by the number of patients in the 10 year
age strata. Continuous variables are presented as mean
(SD) and categorical variables as proportions with 95%
confidence intervals. Statistical calculations were per-
formed with EpiCalc 2000.
Results
Prevalence of atrial fibrillation
Two hundred and fifty-eight charts were identified as pos-
sible atrial fibrillation. Of these 258 charts, a more de-
tailed audit excluded 22 of these patients with a remote
history of atrial fibrillation (no recurrent episodes or per-
sistent arrhythmia during the 2 year period from January
31, 1999 to December 31, 2000), 11 of these patients
were misidentified and did not have atrial fibrillation, and
2 patients whose charts could not be found. In addition,
38 patients who were missed in the original chart audit
were identified in the clinic anticoagulation record books.
As a result of the audit, we identified a total of 261 pa-
tients (Table 1) in our family practice unit who have
chronic atrial fibrillation or paroxysmal atrial fibrillation
with at least one episode of arrhythmia during the 2 year
period above.
The age range of our patients with atrial fibrillation is 40–
97 years with an average age of 78.8 years and a standard
deviation of 9.1 years (Table 2). There was no statistically
significant difference in age between the sexes. The preva-
lence of atrial fibrillation in our population as a whole is
3.9 percent. When considering different age groups, the
prevalence rises as high as 18.2 percent and 18.5 percent
for patients aged 80–89 and 90–99 years respectively (Ta-
ble 1).
Two hundred and nine of the 261 patients were identified
by documentation of atrial fibrillation on the continuous
patient profile (Table 3) at the front of the chart. Many
charts had identifiable documentation in several of the ar-
eas described above. Seventeen patients had documenta-
tion in only one area. With regards to the type of atrial
fibrillation in our 261 patients, 137 patients were classi-
fied as chronic, non-valvular, 113 as paroxysmal, and 11
as valvular.
Treatment
Two hundred and four of our 261 patients with atrial fi-
brillation are currently being treated with warfarin and an-
other 21 patients had been previously treated (Table 4).
This implies that 78.2 percent of our patients are treated
with warfarin, and a total of 86.2 percent have been treat-
ed when including those who were previously treated and
discontinued. There was an age relationship as the per-
centage of patients treated declined with each decade of
age. Only 52% of patients over the age of 90 were treated
with warfarin compared to 78–84% in the 60–89 age
group (Table 5). With regard to treatment alternatives for
anticoagulation, we found that 15 of our 204 patients cur-BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/11
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rently treated with warfarin are taking ASA as well. Fifty-
seven patients are not currently being treated with warfa-
rin – of these, 44 are taking ASA, 2 are taking ticlopidine
and 11 are receiving no anticoagulation.
As stated above, 21 patients who are not currently taking
warfarin have been treated previously. The most common
reason for stopping warfarin was successful electrical car-
dioversion, followed by bleeding complications and pa-
tient choice. The reason for discontinuing treatment was
unclear in 4 patients. Thirty-six of our 261 patients have
never been treated with warfarin. In the majority of pa-
tients, no reason was documented. The reasons that were
documented include previous bleeding not on anticoagu-
lation, fall risk, and patient choice. With regard to previ-
ous complications while taking warfarin, 26 episodes
were documented. All of these were bleeding complica-
tions.
Discussion
The prevalence of atrial fibrillation in active patients at the
family practice unit of Sunnybrook and Women's College
Health Sciences Centre is 3.9 percent for all ages, and rises
Table 1: Prevalence of atrial fibrillation – by age group
Age (years) # of patients # with atrial fibrillation % with atrial fibrillation 95% (C.I.)
0–9 351 0 0 0
10–19 219 0 0 0
20–29 1082 0 0 0
30–39 1130 0 0 0
40–49 873 3 0.3 0.0–0.7
50–59 918 5 0.5 0.1–1.0
60–69 682 28 4.1 2.6–5.6
70–79 689 95 13.8 11.2–16.4
80–89 577 105 18.2 15.0–21.3
90–99 135 25 18.5 12.0–25.1
100+ 7 0 0 0
Total 6663 261 3.9 3.5–4.4
Table 2: Age and sex distribution of patients with atrial 
fibrillation
# Mean Age Standard 
Deviation
Range
Male 133 77.2 9.7 40–93
Female 126 80.5 8.2 46–97
Total 261 78.8 9.1 40–97
Table 3: Identification of atrial fibrillation
Total patients (261)1 # (%) 95% C.I.
Continuous Patient Profile 209 (81) 74.6–84.6
Chart notes 199 (76) 70.5–81.2
Specialist/Emergency 
Room
216 (83) 77.5–87.0
Clinical Note 139 (53) 47.0–59.4
EKG alone 36 (14) 9.9–18.7
117 patients had only one of the above identifying Atrial Fibrillation in 
their chart
Table 4: Anticoagulation treatment methods for patients with 
atrial fibrillation
# (%) 95% C.I.
On Coumadin (n = 204)
Coumadin alone 189 (72.4) 66.5–77.6
Coumadin + Aspirin 15 (5.8) 3.4–9.5
Not on Coumadin (n = 57)
Aspirin alone 44 (16.9) 12.6–22.1
ticlopidine alone 2 (0.8) 0.1–3.0
no treatment 11 (4.2) 2.2–7.6BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/11
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to 16 percent in patients aged 70 and over. This is higher
than the prevalence suggested in previous reports [13].
Several factors may explain our high prevalence. The fam-
ily physicians and residents at Sunnybrook may be more
successful at identifying and documenting cases of atrial
fibrillation than the physicians whose patients were used
in previous studies. In addition, we may have more pa-
tients with atrial fibrillation as a result of being a tertiary
care academic centre with cardiology services on site. Fi-
nally, a complete chart audit, which we performed, is the
gold standard in a primary care setting, for identifying the
most patients with a given condition. The use of a compu-
ter to search billing codes and prescriptions has been
shown to miss as many as 30 percent of the patients in
question [14].
Currently, 78.2 percent of our patients are being treated
with warfarin for stroke prevention. Another 8 percent of
our patients were previously treated with warfarin that
was discontinued for a number of reasons described earli-
er. This implies a coverage rate of 86.2 percent of our atrial
fibrillation patients treated with warfarin. When includ-
ing alternatives to warfarin for anticoagulation, we find
that 95.8 percent of our population are treated.
These results demonstrate that it is possible to achieve
high coverage rates with warfarin in elderly patients with
atrial fibrillation in the primary care setting. Our results
compare favourably with the 10–50 percent coverage re-
ported in previous studies [6–10].
What accounts for such high coverage levels? Our results
may be attributable to our physicians', residents' and
nurses' knowledge of atrial fibrillation due to having a
large number of these patients, as well as being at an aca-
demic centre, with a close working relationship with our
cardiologists. Patient-physician interactions may also play
a role. Warfarin therapy may be framed by clinicians in a
positive manner. It is unclear how the risks and benefits of
warfarin are described to patients in clinical practice, but
research evidence suggests that patients are sensitive to
how risks are framed. Howitt and Armstrong found that
health beliefs were important in determining choice of
treatment and that those seeking a higher level of benefit
were less likely to take warfarin [15]. Protheroe et al found
that a shared decision-making approach led to fewer pa-
tients accepting warfarin therapy than would be expected
by guidelines [16]. How patients in our practice view the
risks and benefits of warfarin therapy, and how it was
communicated to them, will be assessed by a survey and
qualitative study.
One potential risk of our high levels of coverage is proph-
ylaxis of younger patients. Currently, all of our patients
under age 60 with atrial fibrillation are being treated with
warfarin. The most influential set of guidelines for choice
of therapy in atrial fibrillation suggests that patients with
non-valvular atrial fibrillation under age 65 without any
other risk factors for stroke are better treated with ASA
since the bleeding risks on warfarin outweigh the preven-
tive benefits [17].
Is this level of coverage appropriate? Guidelines on anti-
coagulation treatment for atrial fibrillation are highly var-
iable. Thomson et al. showed that guidelines varied in
terms of treatment advice. In their study, 13–100% of pa-
tients would be treated with warfarin [18] Placebo con-
trolled trials favour warfarin treatment. A recently
published systematic review of trials comparing antiplate-
let treatment and anticoagulation suggested that warfarin
may not be superior as a treatment option [19]. However,
Cochrane Reviews support the use of warfarin for atrial fi-
brillation, with or without previous ischaemic events [20–
22]. Thus, the evidence seems to favour warfarin treat-
ment, and the goal for clinicians should be to achieve as
Table 5: Treatment with warfarin (percentage) by decade
Age Range Total # of pts % On warfarin % Not on warfarin % Previously on
warfarin
% Never on warfarin % Ever on warfarin
0–39 0 0 0 0 0 0
40–49 3 100 0 0 0 100
50–59 5 100 0 0 0 100
60–69 28 78.6 21.4 7.1 14.3 85.7
70–79 95 84.2 15.8 9.5 6.3 93.7
80–89 105 77.1 22.9 5.7 17.2 82.8
90–99 25 52 48 16 32 68
All Ages 261 78.2 21.8 8.0 13.8 86.2BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/11
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high a coverage as appropriate given patient preferences.
Identification of which patients are most likely to benefit
from warfarin therapy is facilitated by the development of
decision aids, as clinical practice guidelines are inconsist-
ent or unclear [23].
With regard to our patients who are not currently treated
with warfarin but who have previously been treated, most
of the reasons for discontinuing the medication are iden-
tifiable and appropriate. There is greater uncertainty
around those who have never been treated. In most cases
no reason can be identified.
This study is limited by its potential lack of applicability
in other community settings. However, the predominant-
ly elderly population reflects future demographic trends.
Also, potential cases of atrial fibrillation may have been
missed had these patients not visited the clinic in the pre-
vious two years. Additionally, cases of atrial fibrillation
may have been missed in the chart audit.
Conclusions
In conclusion, this study confirms that atrial fibrillation is
a very common problem in primary care, affecting 18% of
patients over 80. The high prevalence of atrial fibrillation
and the availability of a safe and effective therapy suggests
the utility of screening for atrial fibrillation in the elderly
population. A prospective study to determine whether sys-
tematic screening for atrial fibrillation in the elderly re-
duces stroke morbidity and mortality is recommended.
The study also shows that it is possible to achieve high
coverage rates of warfarin therapy in primary care. This ar-
gues for the development of tools to enable primary care
providers to ascertain the prevalence of atrial fibrillation
in their practice, discover those patients not receiving op-
timal therapy and discuss treatment options with these
patients.
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